From June 25th to 28th, the high-profile China Pharmaceutical and Health Industry Symbiosis Conference (Misi Meeting) was held in Huzhou, Zhejiang. The conference brought together more than 5,000 people from all over the country, including industry experts, association leaders, and representatives of pharmaceutical industry and commerce entrepreneurs, to discuss the future development of the pharmaceutical and health industry. In the authoritative list released at this conference, Huluwa Pharmaceutical Group once again appeared on the "Top 100 Chinese Medicine Enterprises in China".
The ranking of the top 100 has steadily improved
The "2023 China Pharmaceutical Industry Top 100 Series List" focuses on the innovation driving force and professional promotion ability of pharmaceutical industry enterprises, and is one of the widely recognized brands in the domestic pharmaceutical industry.
At the meeting, Huluwa Pharmaceutical Group ranked 40th in the "2023 Top 100 Chinese Medicine Enterprises" in the "2023 China Pharmaceutical Industry Top 100 Series List" by virtue of its excellent innovation ability, solid product quality and stable market influence, ranking 40th, an increase of 3 places from the previous year.
In recent years, Huluwa has actively built a green development ecosystem, with pediatric drugs as its development characteristics, continued to promote the inheritance and innovation of classic famous drug prescriptions, created a full range of children's health around the whole life cycle of children's health, accelerated the layout of children's innovative drugs, health foods, special medical foods, medical devices and other industrial chains, and built the core competitiveness and creativity of enterprises. We will make all-round efforts in innovative research and development, intelligent production, digital operation, etc., and continuously improve the comprehensive strength of enterprise development.
The summit focused on growth
During the meeting, Liu Jingping, Secretary of the Party Committee and Chairman of the Group, was invited to host the summit forum of "Rice on Politics and Top-level Insight", and had an in-depth discussion with many industry experts, scholars and representatives of entrepreneur leaders on the new tests and challenges faced by pharmaceutical people in the current economic environment. Everyone thought together about how to open up new paths and explore new opportunities under the concept of "tenacity and new development".
In the "Mith Dialogue" forum, Liu Jingping and guests from industrial and chain enterprises discussed topics such as "how to seek the growth of pharmaceutical retail in stability". She said that with the gradual enhancement of public health awareness, the country's policy support for the pharmaceutical industry and the big health industry continues to increase, and the big health is becoming a new growth point for the pharmaceutical industry. At the same time, the company continues to improve its professional service capabilities, brand building, and promote cross-border e-commerce, so as to continuously enhance the development resilience of the company.
For a long time, Huluwa has always practiced the corporate mission of "Healthy Chinese Baby", adhered to the guidance of scientific and technological innovation, continuously deepened the value of "production, education, research and application", expanded and optimized the product and market layout with an international vision, and continued to enhance the core competitiveness and brand value of the enterprise.
Source: Huluwa Pharmaceutical Group Audit: Wang Chudie